BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

945 related articles for article (PubMed ID: 19108798)

  • 1. Dosage form design and development.
    Allen LV
    Clin Ther; 2008 Nov; 30(11):2102-11. PubMed ID: 19108798
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Extemporaneous drug formulations.
    Nahata MC; Allen LV
    Clin Ther; 2008 Nov; 30(11):2112-9. PubMed ID: 19108799
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The economics of pediatric formulation development for off-patent drugs.
    Milne CP; Bruss JB
    Clin Ther; 2008 Nov; 30(11):2133-45. PubMed ID: 19108801
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lean Raman imaging for rapid assessment of homogeneity in pharmaceutical formulations.
    Brown SC; Claybourn M; Sievwright D; Fearnside V; Ashman C
    Appl Spectrosc; 2010 Apr; 64(4):442-7. PubMed ID: 20412630
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pediatric drug development: formulation considerations.
    Ali AA; Charoo NA; Abdallah DB
    Drug Dev Ind Pharm; 2014 Oct; 40(10):1283-99. PubMed ID: 24483293
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Crystalline modifications and polymorphism changes during drug manufacture].
    Doelker E
    Ann Pharm Fr; 2002 May; 60(3):161-76. PubMed ID: 12050595
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Solid form screening--a review.
    Aaltonen J; Allesø M; Mirza S; Koradia V; Gordon KC; Rantanen J
    Eur J Pharm Biopharm; 2009 Jan; 71(1):23-37. PubMed ID: 18715549
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lipid excipients and delivery systems for pharmaceutical development: a regulatory perspective.
    Chen ML
    Adv Drug Deliv Rev; 2008 Mar; 60(6):768-77. PubMed ID: 18077051
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The importance of micronization in the design of dosage forms II. Pharmaceutical technological considerations].
    Antal I
    Acta Pharm Hung; 2006; 76(3):149-54. PubMed ID: 17094663
    [TBL] [Abstract][Full Text] [Related]  

  • 10. WHO Expert Committee on specifications for pharmaceutical preparations.
    World Health Organ Tech Rep Ser; 1996; 863():1-194. PubMed ID: 8952445
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overview of drug product development.
    Narayan P
    Curr Protoc Pharmacol; 2011 Dec; Chapter 7():Unit 7.3.1-29. PubMed ID: 22147349
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Importance of interfacial characteristics in pharmaceutical technology].
    Dredán J; Csóka G; Marton S; Antal I
    Acta Pharm Hung; 2003; 73(3):147-51. PubMed ID: 15112437
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enforcement of the current good manufacturing practices for solid oral dosage forms after United States v. Barr Laboratories.
    Jimenez FA
    Food Drug Law J; 1997; 52(1):67-82. PubMed ID: 10346711
    [No Abstract]   [Full Text] [Related]  

  • 14. Recent trends in stabilising peptides and proteins in pharmaceutical formulation - considerations in the choice of excipients.
    Jorgensen L; Hostrup S; Moeller EH; Grohganz H
    Expert Opin Drug Deliv; 2009 Nov; 6(11):1219-30. PubMed ID: 19678792
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stability considerations in liquid dosage forms extemporaneously prepared from commercially available products.
    Glass BD; Haywood A
    J Pharm Pharm Sci; 2006; 9(3):398-426. PubMed ID: 17207422
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Equivalence studies for complex active ingredients and dosage forms.
    Bhattycharyya L; Dabbah R; Hauck W; Sheinin E; Yeoman L; Williams R
    AAPS J; 2005 Nov; 7(4):E786-812. PubMed ID: 16594632
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Medicines for children: a matter of taste.
    Davies EH; Tuleu C
    J Pediatr; 2008 Nov; 153(5):599-604, 604.e1-2. PubMed ID: 18940350
    [No Abstract]   [Full Text] [Related]  

  • 18. In vitro - in vivo correlation: from theory to applications.
    Emami J
    J Pharm Pharm Sci; 2006; 9(2):169-89. PubMed ID: 16959187
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The role of biopharmaceutical parameters in drug development (author's transl)].
    Thoma K
    Arzneimittelforschung; 1976; 26(1A):121-9. PubMed ID: 947191
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Crystal engineering of active pharmaceutical ingredients to improve solubility and dissolution rates.
    Blagden N; de Matas M; Gavan PT; York P
    Adv Drug Deliv Rev; 2007 Jul; 59(7):617-30. PubMed ID: 17597252
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 48.